

Measure #118 (NQF 0066): Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%) – National Quality Strategy Domain: Effective Clinical Care

2017 OPTIONS FOR INDIVIDUAL MEASURES:
REGISTRY ONLY

MEASURES TYPE:
Process

DESCRIPTION:
Percentage of patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period who also have diabetes OR a current or prior Left Ventricular Ejection Fraction (LVEF) < 40% who were prescribed ACE inhibitor or ARB therapy

INSTRUCTIONS:
This measure is to be reported a minimum of **once per performance period** for all patients with CAD seen during the **performance period**. This measure may be reported by eligible clinicians who perform the quality actions described in the measure for the primary management of patients with CAD based on the services provided and the measure-specific denominator coding. Only patients who had at least two denominator eligible visits during the **performance period** will be counted for Reporting Criteria 1 and 2 of this measure.

Measure Reporting:
The listed denominator criteria is used to identify the intended patient population. The numerator options included in this specification are used to submit the quality actions allowed by the measure. The quality-data codes listed do not need to be submitted for registry-based submissions; however, these codes may be submitted for those registries that utilize claims data.

THERE ARE TWO REPORTING CRITERIA FOR THIS MEASURE:

- 1) Patients who are 18 years and older with a diagnosis of CAD with LVEF < 40%

OR

- 2) Patients who are 18 years and older with a diagnosis of CAD who have diabetes

The eligible clinician should submit data on one of the reporting criteria, depending on the clinical findings. If the patient has CAD and LVSD (without a diagnosis of Diabetes), use Denominator Reporting Criteria 1. If the patient has CAD and Diabetes, use Denominator Reporting Criteria 2. If the patient has both diabetes and LVSD, the eligible professional may report quality data for Reporting Criteria 2 and this will count as appropriate reporting for this patient.

REPORTING CRITERIA 1: ALL PATIENTS WITH A DIAGNOSIS OF CAD WITH LVEF < 40% (WITHOUT A DIAGNOSIS OF DIABETES)

DENOMINATOR (REPORTING CRITERIA 1):

All patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period who also have a current or prior LVEF < 40%

Definition:

LVEF < 40% corresponds to qualitative documentation of moderate dysfunction or severe dysfunction

Denominator Criteria (Eligible Cases):

Patients aged ≥ 18 years on date of encounter

AND

Diagnosis for coronary artery disease (ICD-10-CM): I20.0, I20.1, I20.8, I20.9, I21.01, I21.02, I21.09, I21.11, I21.19, I21.21, I21.29, I21.3, I21.4, I22.0, I22.1, I22.2, I22.8, I22.9, I24.0, I24.1, I24.8, I24.9, I25.10, I25.110, I25.111, I25.118, I25.119, I25.2, I25.5, I25.6, I25.700, I25.701, I25.708, I25.709, I25.710, I25.711, I25.718, I25.719, I25.720, I25.721, I25.728, I25.729, I25.730, I25.731, I25.738, I25.739, I25.750, I25.751, I25.758, I25.759, I25.760, I25.761, I25.768, I25.769, I25.790, I25.791, I25.798, I25.799, I25.810, I25.811, I25.812, I25.82, I25.83, I25.89, I25.9, Z95.1, Z95.5, Z98.61

AND

Patient encounter during the performance period (CPT): 99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, 99304, 99305, 99306, 99307, 99308, 99309, 99310, 99324, 99325, 99326, 99327, 99328, 99334, 99335, 99336, 99337, 99341, 99342, 99343, 99344, 99345, 99347, 99348, 99349, 99350

WITHOUT

Telehealth Modifier: GQ, GT

AND

Two Denominator Eligible

Visits

AND

Left Ventricular Ejection Fraction (LVEF) < 40% or documentation of moderately or severely depressed left ventricular systolic function: G8934

NUMERATOR (REPORTING CRITERIA 1):

Patients who were prescribed ACE inhibitor or ARB therapy

Definition:

Prescribed – May include prescription given to the patient for ACE inhibitor or ARB therapy at one or more visits in the measurement period OR patient already taking ACE inhibitor or ARB therapy as documented in current medication list.

Numerator Options:

Performance Met:

Clinician prescribed angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy (**G8935**)

OR

Denominator Exception:

Clinician documented that patient was not an eligible candidate for angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy (e.g., allergy, intolerance, pregnancy, renal failure due to ACE inhibitor, diseases of the aortic or mitral valve, other medical reasons) or (e.g., patient declined, other patient reasons) or (e.g., lack of drug availability, other reasons attributable to the health care system) (**G8936**)

OR

Performance Not Met:

Clinician did not prescribe angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy, reason not given (**G8937**)

OR

REPORTING CRITERIA 2: ALL PATIENTS WITH A DIAGNOSIS OF CAD WHO HAVE DIABETES

DENOMINATOR (REPORTING CRITERIA 2):

All patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period who also have diabetes

Definition:

If a patient has both diabetes and LVSD, reporting criteria #2 will count as appropriate reporting for this patient.

Denominator Criteria (Eligible Cases):

Patients aged ≥ 18 years on date of encounter

AND

Diagnosis for coronary artery disease (ICD-10-CM): I20.0, I20.1, I20.8, I20.9, I21.01, I21.02, I21.09, I21.11, I21.19, I21.21, I21.29, I21.3, I21.4, I22.0, I22.1, I22.2, I22.8, I22.9, I24.0, I24.1, I24.8, I24.9, I25.10, I25.110, I25.111, I25.118, I25.119, I25.2, I25.5, I25.6, I25.700, I25.701, I25.708, I25.709, I25.710, I25.711, I25.718, I25.719, I25.720, I25.721, I25.728, I25.729, I25.730, I25.731, I25.738, I25.739, I25.750, I25.751, I25.758, I25.759, I25.760, I25.761, I25.768, I25.769, I25.790, I25.791, I25.798, I25.799, I25.810, I25.811, I25.812, I25.82, I25.83, I25.89, I25.9, Z95.1, Z95.5, Z98.61

AND

Diagnosis for diabetes (ICD-10-CM): E10.10, E10.11, E10.21, E10.22, E10.29, , E10.319, , E10.3211, E10.3212, E10.3213, E10.3219, , E10.3291, E10.3292, E10.3293, E10.3299, , E10.3311, E10.3312, E10.3313, E10.3319, , E10.3391, E10.3392, E10.3393, E10.3399, , E10.3411, E10.3412, E10.3413, E10.3419, , E10.3491, E10.3492, E10.3493, E10.3499, , E10.3511, E10.3512, E10.3513, E10.3519, E10.3521, E10.3522, E10.3523, E10.3529, E10.3531, E10.3532, E10.3533, E10.3539, E10.3541, E10.3542, E10.3543, E10.3549, E10.3551, E10.3552, E10.3553, E10.3559, , E10.3591, E10.3592, E10.3593, E10.3599, E10.36, E10.39, E10.40, E10.41, E10.42, E10.43, E10.44, E10.49, E10.51, E10.52, E10.59, E10.610, E10.618, E10.620, E10.621, E10.622, E10.628, E10.630, E10.638, E10.641, E10.649, E10.65, E10.69, E10.8, E10.9, E11.00, E11.01, E11.21, E11.22, E11.29, E11.311, E11.319, E11.37X1, E11.37X2, E11.37X3, E11.37X9, , E11.3211, E11.3212, E11.3213, E11.3219, , E11.3291, E11.3292, E11.3293, E11.3299, , E11.3311, E11.3312, E11.3313, E11.3319, , E11.3391, E11.3392, E11.3393, E11.3394, , E11.3411, E11.3412, E11.3414, E11.3419, , E11.3491, E11.3492, E11.3493, E11.3499, , E11.3511, E11.3512, E11.3513, E11.3519, E11.3521, E11.3522, E11.3523, E11.3529, E11.3531, E11.3532, E11.3533, E11.3539, E11.3541, E11.3542, E11.3543, E11.3549, E11.3551, E11.3552, E11.3559, , E11.3591, E11.3592, E11.3593, E11.3599, E11.36, E11.39, E11.40, E11.41, E11.42, E11.43, E11.44, E11.49, E11.51, E11.52, E11.59, E11.610, E11.618, E11.620, E11.621, E11.622, E11.628, E11.630, E11.638, E11.641, E11.649, E11.65, E11.69, E11.8, E11.9, E13.00, E13.01, E13.10, E13.11, E13.21, E13.22, E13.29, E13.311, E13.319, , E13.3211, E13.3212, E13.3213, E13.3219, , E13.3291, E13.3292, E13.3293, E13.3299, , E13.3311, E13.3312, E13.3313, E13.3319, E13.3391, E13.3392, E13.3393, E13.3399, , E13.3411, E13.3412, E13.3413, E13.3419, E13.349, , E13.3511, E13.3512, E13.3513, E13.3519, E13.3521, E13.3522, E13.3523, E13.3529, E13.3531, E13.3532, E13.3533, E13.3539, E13.3541, E13.3542, E13.3543, E13.3549, E13.3551, E13.3552, E13.3553, E13.3559, , E13.3591, E13.3592, E13.3593, E13.3599, E13.36, E13.39, E13.40, E13.41, E13.42, E13.43, E13.44, E13.49, E13.51, E13.52, E13.59, E13.610, E13.618, E13.620, E13.621, E13.622, E13.628, E13.630, E13.638, E13.641, E13.649, E13.65, E13.69, E13.8, E13.9

AND

Patient encounter during the performance period (CPT): 99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, 99304, 99305, 99306, 99307, 99308, 99309, 99310, 99324, 99325, 99326, 99327, 99328, 99334, 99335, 99336, 99337, 99341, 99342, 99343, 99344, 99345, 99347, 99348, 99349, 99350

WITHOUT

Telehealth Modifier: GQ, GT

AND

Two Denominator Eligible Visits

NUMERATOR (REPORTING CRITERIA 2):

Patients who were prescribed ACE inhibitor or ARB therapy

Definition:

Prescribed – May include prescription given to the patient for ACE inhibitor or ARB therapy at one or more visits in the measurement period OR patient already taking ACE inhibitor or ARB therapy as documented in current medication list.

Numerator Options:***Performance Met:***

Angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy prescribed (**G8473**)

OR

Denominator Exception:

Angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy not prescribed for reasons documented by the clinician (e.g., allergy, intolerance, pregnancy, renal failure due to ACE inhibitor, diseases of the aortic or mitral valve, other medical reasons) or (e.g., patient declined, other patient reasons) or (e.g., lack of drug availability, other reasons attributable to the health care system) (**G8474**)

OR

Performance Not Met:

Angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy not prescribed, reason not given (**G8475**)

RATIONALE:

Nonadherence to cardioprotective medications is prevalent among outpatients with coronary artery disease and can be associated with a broad range of adverse outcomes, including all-cause and cardiovascular mortality, cardiovascular hospitalizations, and the need for revascularization procedures.

In the absence of contraindications, ACE inhibitors or ARBs are recommended for all patients with a diagnosis of coronary artery disease and diabetes or reduced left ventricular systolic function. ACE inhibitors remain the first choice, but ARBs can now be considered a reasonable alternative. Both pharmacologic agents have been shown to decrease the risk of death, myocardial infarction, and stroke. Additional benefits of ACE inhibitors include the reduction of diabetic symptoms and complications for patients with diabetes.

CLINICAL RECOMMENDATION STATEMENTS:

The following evidence statements are quoted verbatim from the referenced clinical guidelines.

2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease (SIHD)

RENIN-ANGIOTENSIN-ALDOSTERONE BLOCKER THERAPY

ACE inhibitors should be prescribed in all patients with SIHD who also have hypertension, diabetes mellitus, LVEF 40% or less, or CKD, unless contraindicated. (Class I Recommendation Level of Evidence: A)

ARBs are recommended for patients with SIHD who have hypertension, diabetes mellitus, LV systolic dysfunction, or CKD and have indications for, but are intolerant of, ACE inhibitors. (Class I Recommendation, Level of Evidence: A)

COPYRIGHT:

Physician performance measures and related data specifications were developed by the American Medical Association (AMA) convened Physician Consortium for Performance Improvement® (PCPI®), the American College of Cardiology (ACC), and the American Heart Association (AHA) to facilitate quality improvement activities by physicians. These performance measures are not clinical guidelines and do not establish a standard of medical care, and have not been tested for all potential applications. While copyrighted, they can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the performance measures for commercial gain, or incorporation of the performance measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the measures require a license agreement between the user and the AMA (on behalf of the PCPI) or the ACC or the AHA. Neither the AMA, ACC, AHA, the PCPI nor its members shall be responsible for any use of these measures.


THE MEASURES AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND.

© 2014 American College of Cardiology, American Heart Association and American Medical Association. All Rights Reserved.

Limited proprietary coding is contained in the measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, the ACC, the AHA, the PCPI and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.

CPT® contained in the measures specifications is copyright 2016 American Medical Association. LOINC® copyright 2004-2016 Regenstrief Institute, Inc. This material contains SNOMED CLINICAL TERMS (SNOMED CT®) copyright 2004-2016 International Health Terminology Standards Development Organization. All Rights Reserved. Use of SNOMED CT® is only authorized within the United States.

**#118 NQF #0066: Coronary Artery Disease (CAD):
Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB)
Therapy-Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%)
Reporting Criteria One**



*This measure has two reporting criteria which should be aggregated to one calculation. Please refer to the sample calculation.

**See the posted Measure Specification for specific coding and instructions to report this measure.

***Left Ventricular Ejection Fraction < 40% has been moved to the denominator of this measure to identify the measure's intended eligible population more accurately. This flow should be followed very carefully since the eligible population in this flow differs from the one posted in the Measure Specification.

NOTE: Reporting Frequency: Patient-process

CPT only copyright 2016 American Medical Association. All rights reserved.
The measure diagrams were developed by CMS as a supplemental resource to be used in conjunction with the measure specifications. They should not be used alone or as a substitution for the measure specification.
v1

2017 Registry Individual Flow
#118 NQF #0066: Coronary Artery Disease (CAD):
Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB)
Therapy-Diabetes or Left Ventricular Systolic Dysfunction (LVSD < 40%)
Reporting Criteria Two



*This measure has two reporting criteria which should be aggregated to one calculation. Please refer to the sample calculation.

**See the posted Measure Specification for specific coding and instructions to report this measure.

**If a patient is diagnosed with diabetes, reporting option #2 is appropriate for reporting on this patient.

NOTE: Reporting Frequency: Patient-process

CPT only copyright 2016 American Medical Association. All rights reserved.
 The measure diagrams were developed by CMS as a supplemental resource to be used in conjunction with the measure specifications. They should not be used alone or as a substitution for the measure specification.

v1

2017 Registry Individual Flow
#118 NQF #0066: Coronary Artery Disease (CAD):
Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB)
Therapy-Diabetes or Left Ventricular Systolic Dysfunction (LVSD < 40%)

SAMPLE CALCULATIONS:

Data Completeness=

$$\frac{\text{Performance Met (a}^1\text{+a}^2\text{=8 patients) + Denominator Exception (b}^1\text{+b}^2\text{=2 patients) + Performance Not Met (c}^1\text{+c}^2\text{=4 patients)}}{\text{Eligible Population / Denominator (d}^1\text{+d}^2\text{=16 patients)}} = \frac{14 \text{ patients}}{16 \text{ patients}} = 87.50\%$$

Performance Rate=

$$\frac{\text{Performance Met (a}^1\text{+a}^2\text{=8 patients)}}{\text{Data Completeness Numerator (14 patients) – Denominator Exception (b}^1\text{+b}^2\text{=2 patients)}} = \frac{8 \text{ patients}}{12 \text{ patients}} = 66.67\%$$

*This measure has two reporting criteria which should be aggregated to one calculation. Please refer to the sample calculation.

**See the posted Measure Specification for specific coding and instructions to report this measure.

**If a patient is diagnosed with diabetes, reporting option #2 is appropriate for reporting on this patient.

NOTE: Reporting Frequency: Patient-process

CPT only copyright 2016 American Medical Association. All rights reserved.
The measure diagrams were developed by CMS as a supplemental resource to be used in conjunction with the measure specifications. They should not be used alone or as a substitution for the measure specification.

2017 Registry Individual Measure Flow

#118 NQF #0066: Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy – Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%)

Please refer to the specific section of the Measure Specification to identify the denominator and numerator information for use in reporting this Individual Measure.

1. Start with Denominator
2. Check Patient Age:
 - a. If the Age is greater than or equal to 18 years of age on Date of Service and equals No during the measurement period, do not include in Eligible Patient Population. Stop Processing.
 - b. If the Age is greater than or equal to 18 years of age on Date of Service and equals Yes during the measurement period, proceed to check Patient Diagnosis.
3. Check Patient Diagnosis:
 - a. If Diagnosis of CAD as Listed in the Denominator equals No, do not include in Eligible Patient Population. Stop Processing.
 - b. If Diagnosis of CAD as Listed in the Denominator equals Yes, proceed to check Left Ventricular Ejection Fraction < 40%.
4. Check Left Ventricular Ejection Fraction < 40%:
 - a. If Left Ventricular Ejection Fraction < 40% equals No, do not include in Eligible Patient Population. Stop Processing.
 - b. If Left Ventricular Ejection Fraction < 40% equals Yes, proceed to check Encounter Performed.
5. Check Encounter Performed:
 - a. If Encounter as Listed in the Denominator equals No, do not include in Eligible Patient Population. Stop Processing.
 - b. If Encounter as Listed in the Denominator equals Yes, proceed to check Telehealth.
6. Check Telehealth Modifier:
 - a. If Telehealth Modifier equals Yes, do not include in Eligible Patient Population. Stop Processing.
 - b. If Telehealth Modifier equals No, proceed to check Encounter Performed.
7. Check Encounter Performed:
 - a. If Two Denominator Eligible Visits equals No, do not include in Eligible Patient Population. Stop Processing.
 - b. If Two Denominator Eligible Visits equals Yes, proceed to check Diagnosis.
8. Check Diagnosis of Diabetes as Listed in the Denominator:

- a. If Diagnosis of Diabetes as Listed in the Denominator equals Yes, proceed to Report Criteria #2.
 - b. If Diagnosis of Diabetes as Listed in the Denominator equals No, include in the Eligible population.
9. Denominator Population:
- a. Denominator population is all Eligible Patients in the denominator. Denominator is represented as Denominator in the Sample Calculation listed at the end of this document. Letter d equals 8 patients in the sample calculation.
10. Check Clinician Prescribed Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB):
- a. If Clinician Prescribed Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) equals Yes, include in Data Completeness Met and Performance Met.
 - b. Data Completeness Met and Performance Met letter is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a1 equals 4 patients in Sample Calculation.
 - c. If Clinician Prescribed Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) equals No, proceed to Clinician Documented that Patient was Not an Eligible Candidate for Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy.
11. Check Clinician Documented That Patient was not an Eligible Candidate for Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy:
- a. If Clinician Documented that Patient was Not an Eligible Candidate for Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy equals Yes, include in Data Completeness Met and Denominator Exception.
 - b. Data Completeness Met and Denominator Exception letter is represented in the Data Completeness in the Sample Calculation listed at the end of this document. Letter b1 equals 1 patient in the Sample Calculation.
 - c. If Clinician Documented that Patient was Not an Eligible Candidate for Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy equals No, proceed to Clinician did Not Prescribe Angiotensin Converting Enzyme (ACE) or Angiotensin Receptor Blocker (ARB), Reason Not Given.
12. Check Clinician Did Not Prescribe Angiotensin Converting Enzyme (ACE) or Angiotensin Receptor Blocker (ARB), Reason not Given:
- a. If Clinician Did Not Prescribe Angiotensin Converting Enzyme (ACE) or Angiotensin Receptor Blocker (ARB), Reason Not Given equals Yes, include in the Data Completeness Met and Performance Not Met.
 - b. Data Completeness Met and Performance Not Met letter is represented in the Data Completeness in the Sample Calculation listed at the end of this document. Letter c1 equals 2 patients in the Sample Calculation.
 - c. If Clinician Did Not Prescribe Angiotensin Converting Enzyme (ACE) or Angiotensin Receptor Blocker (ARB), Reason Not Given equals No, proceed to Data Completeness Not Met.

13. Check Data Completeness Not Met:

- a. If Data Completeness Not Met equals No, Quality Data Code or equivalent not reported. 1 patient has been subtracted from the Data Completeness numerator in the sample calculation.

SAMPLE CALCULATIONS:

Data Completeness=

$$\frac{\text{Performance Met (a}^1\text{+a}^2\text{=8 patients) + Denominator Exception (b}^1\text{+b}^2\text{=2 patients) + Performance Not Met (c}^1\text{+c}^2\text{=4 patients)}}{\text{Eligible Population / Denominator (d}^1\text{+d}^2\text{=16 patients)}} = \frac{14 \text{ patients}}{16 \text{ patients}} = 87.50\%$$

Performance Rate=

$$\frac{\text{Performance Met (a}^1\text{+a}^2\text{=8 patients)}}{\text{Data Completeness Numerator (14 patients) – Denominator Exception (b}^1\text{+b}^2\text{=2 patients)}} = \frac{8 \text{ patients}}{12 \text{ patients}} = 66.67\%$$

2017 Registry Individual Measure Flow

#118 NQF #0066: Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy – Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%)

1. Start Reporting Criteria #2
2. Start with Denominator
3. Check Patient Age:
 - a. If the Age is greater than or equal to 18 years of age on Date of Service and equals No during the measurement period, do not include in Eligible Patient Population. Stop Processing.
 - b. If the Age is greater than or equal to 18 years of age on Date of Service and equals Yes during the measurement period, proceed to check Patient Diagnosis.
4. Check Patient Diagnosis:
 - a. If Diagnosis of CAD as Listed in the Denominator equals No, do not include in Eligible Patient Population. Stop Processing.
 - b. If Diagnosis of CAD as Listed in the Denominator equals Yes, proceed to check Encounter Performed.
5. Check Encounter Performed:
 - a. If Encounter as Listed in the Denominator equals No, do not include in Eligible Patient Population. Stop Processing.
 - b. If Encounter as Listed in the Denominator equals Yes, proceed to Check Telehealth
6. Check Telehealth Modifier:
 - a. If Telehealth Modifier equals Yes, do not include in Eligible Patient Population. Stop Processing.
 - b. If Telehealth Modifier equals No, proceed to Encounter Performed.
7. Check Encounter Performed:
 - a. If Two Denominator Eligible Visits equals No, do not include in Eligible Patient Population. Stop Processing.
 - b. If Two Denominator Eligible Visits equals Yes, proceed to Diagnosis of Diabetes as Listed in the Denominator.
8. Check Diagnosis of Diabetes as Listed in the Denominator:
 - a. If Diagnosis of Diabetes as Listed in the Denominator equals No, proceed to Report Criteria #1.
 - b. If Diagnosis of Diabetes as Listed in the Denominator equals Yes, include in the Eligible population.
9. Denominator Population:

- a. Denominator population is all Eligible Patients in the denominator. Denominator is represented as Denominator in the Sample Calculation listed at the end of this document. Letter d equals 8 patients in the sample calculation.
10. Check Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy Prescribed:
 - a. If Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy Prescribed equals Yes, include in Data Completeness Met and Performance Met.
 - b. Data Completeness Met and Performance Met letter is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a2 equals 4 patients in Sample Calculation.
 - c. If Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy Prescribed equals No, proceed to Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy not Prescribed for Reasons Documented by the Clinician.
11. Check Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy not Prescribed for Reasons Documented by the Clinician:
 - a. If Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy not Prescribed for Reasons Documented by the Clinician equals Yes, include in Data Completeness Met and Denominator Exception.
 - b. Data Completeness Met and Denominator Exception letter is represented in the Data Completeness in the Sample Calculation listed at the end of this document. Letter b2 equals 1 patient in the Sample Calculation.
 - c. If Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy not Prescribed for Reasons Documented by the Clinician equals No, proceed to Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy not Prescribed, Reason not Given.
12. Check Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy not Prescribed, Reason not Given:
 - a. If Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy not Prescribed, Reason not Given equals Yes, include in the Data Completeness Met and Performance Not Met.
 - b. Data Completeness Met and Performance Not Met letter is represented in the Data Completeness in the Sample Calculation listed at the end of this document. Letter c2 equals 2 patients in the Sample Calculation.
 - c. If Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy not Prescribed, Reason not Given equals No, proceed to Data Completeness Not Met.
13. Check Data Completeness Not Met:
 - a. If Data Completeness Not Met equals No, Quality Data Code or equivalent not reported. 1 patient has been subtracted from the Data Completeness numerator in the sample calculation.

SAMPLE CALCULATIONS:

Data Completeness=

$$\frac{\text{Performance Met (a}^1\text{+a}^2\text{=8 patients) + Denominator Exception (b}^1\text{+b}^2\text{=2 patients) + Performance Not Met (c}^1\text{+c}^2\text{=4 patients)}}{\text{Eligible Population / Denominator (d}^1\text{+d}^2\text{=16 patients)}} = \frac{14 \text{ patients}}{16 \text{ patients}} = 87.50\%$$

Performance Rate=

$$\frac{\text{Performance Met (a}^1\text{+a}^2\text{=8 patients)}}{\text{Data Completeness Numerator (14 patients) – Denominator Exception (b}^1\text{+b}^2\text{=2 patients)}} = \frac{8 \text{ patients}}{12 \text{ patients}} = 66.67\%$$